Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
609
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 457–468 of 609 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 2 Interventional

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT05643638
Site status not listed — check the official record
View directory record Official record
Conditions
Graft Versus Host Disease, Acute
Interventions
CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Corticosteroids, Placebo
Biological · Drug
Lead sponsor
Cynata Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 30, 2026, 6:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

NCT07604285
Site status not listed — check the official record
View directory record Official record
Conditions
Glioblastoma
Interventions
MT-125
Drug
Lead sponsor
Myosin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Jul 29, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

NCT06347796
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Conventional Surgery, Middle Meningeal Artery Embolization (MMAE)
Procedure · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Aug 3, 2026, 4:38 AM EDT
Active, not recruiting Phase 2 Interventional

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753
Site status not listed — check the official record
View directory record Official record
Conditions
BMM, Bone Marrow Mastocytosis, ISM, Mastocytosis, Mastocytosis, Indolent, Mastocytosis, Systemic, SSM, Smoldering Systemic Mastocytosis
Interventions
Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 11:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 4, 2026, 8:03 PM EDT
Active, not recruiting Phase 1 Interventional

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Carboplatin, Cisplatin, Datopotamab deruxtecan, KEYTRUDA®
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 8:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

NCT04042831
Site status not listed — check the official record
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 14, 2026, 10:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591
Status at this site: Recruiting
View directory record Official record
Conditions
Lung Cancer, MTAP Deletion, NSCLC, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, RAS Mutation, Thoracic Cancer
Interventions
RMC-6236, RMC-9805, TNG462, gemcitabine/nab-paclitaxel, mFOLFIRINOX
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 30, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926
Status at this site: Recruiting
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Enterra Therapy System
Device
Lead sponsor
Enterra Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 13, 2026, 3:44 PM EDT
Recruiting Phase 3 Interventional

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971
Status at this site: Recruiting
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 29, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804
Site status not listed — check the official record
View directory record Official record
Conditions
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Echocardiography, Lenalidomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 9, 2026, 8:07 PM EDT
Recruiting Phase 4 Interventional

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

NCT05837091
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
24-hour polysomnography, Axivity device, Low Sodium Oxybate, Nextsense EEG earbuds
Diagnostic Test · Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 1:08 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.